Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan

por Chaturvedi, Nagendra K., McGuire, Timothy R., Coulter, Don W., Shukla, Ashima, McIntyre, Erin M., Sharp, John Graham, Joshi, Shantaram S.
Publicado 2016

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma

por Kling, Matthew J., Griggs, Connor N., McIntyre, Erin M., Alexander, Gracey, Ray, Sutapa, Challagundla, Kishore B., Joshi, Shantaram S., Coulter, Don W., Chaturvedi, Nagendra K.
Publicado 2021

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

por Kling, Matthew J., Kesherwani, Varun, Mishra, Nitish K., Alexander, Gracey, McIntyre, Erin M., Ray, Sutapa, Challagundla, Kishore B., Joshi, Shantaram S., Coulter, Don W., Chaturvedi, Nagendra K.
Publicado 2022

STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo

por Rohrer, Kyle A., Song, Heyu, Akbar, Anum, Chen, Yingling, Pramanik, Suravi, Wilder, Phillip J., McIntyre, Erin M., Chaturvedi, Nagendra K., Bhakat, Kishor K., Rizzino, Angie, Coulter, Don W., Ray, Sutapa
Publicado 2023

Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513

por Coulter, Don W., McGuire, Timothy R., Sharp, John G., McIntyre, Erin M., Dong, Yuxiang, Wang, Xiaofang, Gray, Shawn, Alexander, Gracey R., Chatuverdi, Nagendra K., Joshi, Shantaram S., Chen, Xiaoyu, Vennerstrom, Jonathan L.
Publicado 2016

Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus

por McGuire, Timothy R., Coulter, Don W., Bai, Dachang, Sughroue, Jason A., Li, Jerry, Yang, Zunhua, Qiao, Zhen, Liu, Yan, Murry, Daryl J., Chhonker, Yashpal S., McIntyre, Erin M., Alexander, Gracey, Sharp, John G., Li, Rongshi
Publicado 2019